Idelalisib plus rituximab extended survival in previously treated CLL Healio NEW ORLEANS — The addition of idelalisib to rituximab significantly extended survival in heavily pretreated patients with relapsed chronic lymphocytic leukemia, according to phase 3 study results presented at the ASH Annual Meeting and Exposition. Idelalisib/Rituximab Combo Improves Survival in Late-Stage CLL Gileads Pipeline Encourages |
